Background
Methods
Study design
Study sites
Study population
Treatment
Patient follow-up
Data analysis
Ethics
Results
Baseline characteristics
Characteristic | Total (n = 140) | Ecological zone | p value | |
---|---|---|---|---|
Forest (n = 59) | Savannah (n = 81) | |||
Male/female | 74/66 | 29/30 | 45/36 | 0.563 |
Age group | ||||
<5 years | 82 (58.6 %) | 26 (44.1 %) | 56 (69.1 %) | 0.005 |
5–9 years | 58 (41.4 %) | 33 (55.9 %) | 25 (30.9 %) | |
Axillary temperature in °C | ||||
Mean temperature (sd)a
| 37.8 (0.9) | 37.5 (0.1) | 38.1 (1.1) | 0.000 |
Range (min, max) | 35.2, 40.0 | 36.9, 37.5 | 35.2, 40.0 | |
Parasitaemia/µl | ||||
Geometric mean | 32,479 | 44,669 | 25,750 | 0.001 |
Range (min, max) | (1000, 228,040) | (1000, 228,040) | (1029, 170,840) | |
Haemoglobin level in g/dl | ||||
Mean (sd)a
| 8.7 (1.6) | 8.7 (1.0) | 8.7 (1.9) | 1.000 |
Range (min, max) | (5.4, 13.9) | (6.0, 13.9) | (5.4, 13.9) | |
Previous anti-malarial intake | 12 (8.6 %) | 0 | 12 (14.8 %)b
| 0.005 |
Characteristic | Total (n = 170) | Ecological zone | p value | |
---|---|---|---|---|
Forest (n = 124) | Savannah (n = 46) | |||
Male/female | 77/93 | 56/68 | 21/25 | 0.907 |
Age group | ||||
<5 years | 110 (64.7 %) | 81 (65.3 %) | 29 (63.0 %) | 0.924 |
5–9 years | 60 (35.3 %) | 43 (34.7 %) | 17 (37.0 %) | |
Axillary temperature in °C | ||||
Mean temperature (sd)a
| 38.1 (1.0) | 38.2 (1.0) | 37.9 (1.1) | 0.093 |
Range (min, max) | 35.6, 40.2 | 35.6, 40.2 | 35.9, 40.1 | |
Parasitaemia/µl | ||||
Geometric mean | 39,983 | 38,665 | 43,766 | 0.415 |
Range (min, max) | (1080, 240,840) | (1080, 239,890) | (1280, 240,840) | |
Haemoglobin level in g/dl | ||||
Mean (sd)a
| 10.2 (1.5) | 10.2 (1.6) | 10.3 (1.2) | 0.695 |
Range (min, max) | (5.6, 14.4) | (5.6, 13.1) | (6.4, 14.4) |
Primary outcomes
Anti-malarial drug | Treatment outcome | Total | Ecological zone | |
---|---|---|---|---|
Forest | Savannah | |||
AS-AQ | n = 140 | n = 59 | n = 81 | |
ETF | 0 | 0 | 0 | |
LCF | 1 | 1 | 0 | |
LPF | 2 | 0 | 2 | |
ACPR | 122 | 49 | 73 | |
NAa
| 15 | 9b
| 6c
| |
AL | n = 170 | n = 124 | n = 46 | |
ETF | 0 | 0 | 0 | |
LCF | 8 | 8 | 0 | |
LPF | 24 | 10 | 14 | |
ACPR | 121 | 103 | 18 | |
NAa
| 17 | 3d
| 14e
|
Secondary outcomes
Anti-malarial | Ecological zone | ||||
---|---|---|---|---|---|
Forest | p value | Savannah | p value | ||
AS-AQ | Day 0 mean Hb (sd) | 8.7 (1.0) | 0.295 | 8.7 (1.9) | |
Day 14 mean Hb (sd) | 8.9 (1.0) | 0.006 | 9.6 (1.8) | 0.002 | |
Day 28 mean Hb (sd) | 9.2 (0.8) | 10.3 (2.1) | <0.001 | ||
AL | Day 0 mean Hb (sd) | 10.2 (1.6) | 10.3 (1.2) | ||
Day 14 mean Hb (sd) | 10.4 (1.3) | 0.299 | ** | ||
Day 28 mean Hb (sd) | 10.7 (1.3) | 0.011 | ** |